ERBB2 and breast cancer: Patients with metastatic HER2 + breast cancer and high levels of miR-19a-3p (good prognosis) had a higher percentage of circulating activated CD4 + T cells and NK cells compared to those with low levels of miR-19a-3p (poor prognosis)